Clinical trials: Breast Tumor Tissue
Breast Cancer, Cancer Survivor
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
RATIONALE: Magnesium oxide may help relieve hot flashes symptoms in women with a history of breast cancer. PURPOSE: This randomized clinical trial studies how well a high-dose or a low-dose of magnesium oxide works compared to…
- Conditions
- Breast Cancer, Cancer Survivor, Hot Flashes
- Trial name
- NCT01439945
- Testing
- magnesium oxide
- Where
- 283 sites in United States
- Volunteers
- 289 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Ovarian Neoplasms, Endometrial Neoplasms
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors.
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06400472
- Testing
- Sofe-M, bevacizumab, carboplatin
- Where
- 25 sites in United States, Australia and 5 more
- Volunteers
- 575 people
- Sponsor
- Eli Lilly and Company
Breastcancer, Phyllodes Breast Tumor
Establishing Technique for PECS2 Catheter Insertion
The investigators are trying to establish an easy technique for insertion of a catheter for continuous infusion while performing pectoral type 2 (serratus) block, as a post operative pain controlling measure for cases undergoing…
- Trial name
- ETCI (NCT03030677)
- Testing
- Pectoralis II block & catheter without Lidocaine dissection, Pectoralis II block & catheter with Lidocaine dissection, catheter insertion
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Kasr El Aini Hospital
Breast Cancer
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
CMF (cyclophosphamide, methotrexate, fluorouracil) is used to treat early stage breast cancer. The combination, of these three drugs, has been used for approximately 30 years in the treatment of breast cancer, and has been shown…
- Trial name
- NCT00615901
- Testing
- cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Early-stage Breast Cancer
Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming
This research is being done to test the feasibility of 24-48 hours of water-only fasting to improve delivery of 4 cycles of chemotherapy in those receiving breast cancer treatment either before or after surgery.
- Trial name
- GAMMER (NCT06536881)
- Testing
- Fasting
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer
Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance
The goal of this randomized, pragmatic clinical trial is to evaluate an endocrine therapy dose-frequency escalation strategy and its effects on tolerability and compliance.
- Trial name
- REaCT-TEMPO (NCT05754528)
- Testing
- Standard of care administration of Endocrine therapy, Dose-frequency escalation administration of Endocrine therapy
- Where
- 2 sites in Canada
- Volunteers
- 240 people
- Sponsor
- Ottawa Hospital Research Institute
TNBC - Triple-Negative Breast Cancer
LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
To evaluate the efficacy and safety of LM108 plus toripalimab plusnab-paclitaxel or eribulin as first-line or post-line treatment in patients with metastatic triple-negative breast cancer.
- Trial name
- NCT06387628
- Testing
- LM-108, Toripalimab, Eribulin
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Fudan University
Breast Cancer, Radiation Toxicity
Pre- or Postoperative Accelerated Radiotherapy
20 non-metastasized breast cancer patients receiving neoadjuvant chemotherapy will be randomized between preop or postop RT. Patients with clinically suspicious axillary lymph nodes will receive a fine needle biopsy.
- Trial name
- POP-ART (NCT03783364)
- Testing
- Radiotherapy
- Where
- 2 sites in Belgium
- Volunteers
- 20 people
- Sponsor
- University Hospital, Ghent
Breast Cancer
Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer
The purpose of this study is to determine the effectiveness and safety of administering Herceptin in combination with Taxol (paclitaxel) in the treatment of women with HER2-positive, early stage breast cancer prior to surgery.
- Trial name
- NCT00136539
- Testing
- Herceptin, Taxol, Adriamycin
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Harold J. Burstein, MD, PhD
Breast Carcinoma, Recurrent Breast Carcinoma
Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
This randomized phase III trial studies first-line chemotherapy and trastuzumab to compare how well they work when given with or without bevacizumab in treating patients with breast cancer that overexpresses human epidermal…
- Conditions
- Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer
- Trial name
- NCT00520975
- Testing
- Bevacizumab, Carboplatin, Paclitaxel
- Where
- 373 sites in United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
Breast Carcinoma; Magnetic Resonance Imaging；OGSE
Study on the Correlation Between the Quantitative Parameters of Mr Mean Cell Size Imaging and the Histopathological Characteristics of Breast Cancer
Patients with breast masses and suspected breast malignancies by ultrasound / mammography were prospectively included. After routine MRI scanning, all patients underwent average cell size imaging sequence scanning, and finally…
- Trial name
- OGSE (NCT05373628)
- Testing
- Gradient and pulse imaging
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Benign Breast Disease, Breast Cancer
Prolactin Receptor and Breast Diseases
Prolactin is known to play an important role in breast development and differentiation. Thus proliferative breast diseases are good models to unravel PRl / PRLR function in proliferative processes.
- Trial name
- Prolacsein (NCT00842465)
- Testing
- blood collection for hormonal status analysis, breast Biopsy or surgery, blood collection
- Where
- France
- Volunteers
- 735 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Neoplasms
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
To compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already received 2-3 years of adjuvant tamoxifen, in terms…
- Trial name
- IES (NCT00038467)
- Testing
- Tamoxifen, Exemestane
- Where
- 377 sites in United States, Argentina and 35 more
- Volunteers
- 4,740 people
- Sponsor
- Pfizer
Breast Cancer
Effect of Breast Implants om Mammography Screening
The purpose of the study is to survey how many women have breast implants in the mammography screening population and the effect of implants on the number and type of examinations and on costs.
- Trial name
- NCT05222100
- Testing
- Mammography screening
- Where
- Sweden
- Volunteers
- 2,500 people
- Sponsor
- Vastra Gotaland Region
Breast Cancer
A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
This study is being done for the following reasons: The study has two parts. The purpose of the first part (Phase I) of the study is to find out the highest dose of neratinib that can be given safely with T-DM1.
- Trial name
- NCT02236000
- Testing
- Neratinib, T-DM1
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- NSABP Foundation Inc
Decision Support Technique, Breast Cancer
E-Based Technology to Provide Decision Aid on Breast Reconstruction for Women With Breast Cance
Using decision aids has been demonstrated to support women to make treatment decision effectively. However, these studies focused on the decision of receiving breast conservative surgery or mastectomy, had short term follow-ups…
- Trial name
- NCT04190992
- Testing
- E-based & personalized breast reconstruction surgery decision aid, Usual care
- Where
- Taiwan
- Volunteers
- 176 people
- Sponsor
- National Cheng-Kung University Hospital
Breast Cancer
Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy…
- Trial name
- NCT00002627
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- St. Louis University
Breast Cancer
Real-World Treatment of ADC-Resistant HER2-Low Advanced Breast Cancer
This is a multicenter, retrospective real-world study aiming to evaluate the efficacy and safety of post-antibody-drug conjugate (post-ADC) treatment strategies in patients with HER2-low advanced breast cancer who have developed…
- Trial name
- NCT07587983
- Where
- China
- Volunteers
- 220 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer
Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer
This pilot study evaluates the use of high-intensity focused ultrasound (HIFU) combined with pembrolizumab in patients with metastatic breast cancer.
- Trial name
- Breast-48 (NCT03237572)
- Testing
- Pembrolizumab, High-intensity focused ultrasound (HIFU)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Patrick Dillon, MD
Breast Cancer
Prospective Analysis of Changes in Background Parenchymal Enhancement (BPE) and Amount of Fibroglandular Tissue on Breast MRI
Tamoxifen is a hormonal treatment for breast cancer. It prevents recurrent disease and decreases death. Tamoxifen is given to women with and at high risk for breast cancer.
- Trial name
- NCT01297231
- Testing
- MRI
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.